Secarna Pharmaceuticals GmbH & Co. KG

BRIEF

published on 10/31/2024 at 16:08, 1 month 20 days ago

Secarna Pharmaceuticals Appoints New CEO Konstantin Petropoulos

CEO Appointment Biopharmaceuticals Secarna Pharmaceuticals Konstantin Petropoulos Oligonucleotide Therapeutics
PRESS RELEASE

published on 10/31/2024 at 16:03, 1 month 20 days ago

Secarna Announces Appointment of Konstantin Petropoulos as Chief Executive Office
Secarna Pharmaceuticals announces Konstantin Petropoulos as new CEO, succeeding Alexander Gebauer, focusing on oligonucleotide therapeutics. Petropoulos brings extensive industry experience

Business Development CEO Appointment Secarna Pharmaceuticals Konstantin Petropoulos Oligonucleotide Therapeutics
BRIEF

published on 09/09/2024 at 14:05, 3 months 12 days ago

Secarna Pharmaceuticals to Showcase ASO Potential at Inflammasome Therapeutics Summit

Secarna Pharmaceuticals ASOs Inflammation NLRP3 Inflammasome Therapeutics Summit
PRESS RELEASE

published on 09/09/2024 at 14:00, 3 months 12 days ago

Secarna Pharmaceuticals will present data at 6th Inflammasome Therapeutics Summit demonstrating the potential of ASOs to target the expression of NLRP3
Secarna Pharmaceuticals presents ASO data targeting NLRP3 at Inflammasome Therapeutics Summit, showcasing potential in inflammatory disease treatment

Secarna Pharmaceuticals ASOs NLRP3 Inflammasome Summit Inflammatory Disease
BRIEF

published on 09/04/2024 at 14:05, 3 months 17 days ago

Secarna Establishes Oncology Advisory Board with Experts Prof. Dr. Eggermont and Prof. Dr. Zippelius

Scientific Advisory Board Secarna Pharmaceuticals Oncology Experts SECN-15 Neuropilin 1
PRESS RELEASE

published on 09/04/2024 at 14:00, 3 months 17 days ago

Secarna establishes Scientific Advisory Board with leading oncology experts Prof. Dr. Eggermont and Prof. Dr. Zippelius
Secarna Pharmaceuticals GmbH & Co. KG establishes an oncology Scientific Advisory Board with leading experts Prof. Dr. Eggermont and Prof. Dr. Zippelius to guide the development of SECN-15 and the oncology pipeline

Scientific Advisory Board Oncology Therapeutics Secarna Pharmaceuticals SECN-15
BRIEF

published on 07/22/2024 at 14:05, 4 months 30 days ago

Secarna Pharmaceuticals Publishes New Data on LNA-Modified ASOs

Secarna Pharmaceuticals ASOs Immunostimulatory Potential TLR9 Nucleic Acid Therapeutics
PRESS RELEASE

published on 07/22/2024 at 14:00, 4 months 30 days ago

Secarna Pharmaceuticals publishes new data in Nucleic Acid Therapeutics showcasing strategies to detect and prevent immunostimulatory potential of LNA-modified ASOs
Secarna Pharmaceuticals publishes new data in Nucleic Acid Therapeutics highlighting strategies to detect and prevent immunostimulatory potential of LNA-modified ASOs

Secarna Pharmaceuticals ASOs Immunostimulatory Potential Nucleic Acid Therapeutics LNA-modified
BRIEF

published on 05/28/2024 at 13:05, 6 months 24 days ago

Secarna Pharmaceuticals and Orbit Discovery Enter Collaboration to Develop Peptide-Conjugated Antisense Therapeutics

Collaboration Secarna Pharmaceuticals Orbit Discovery Antisense Therapeutics Peptide-Conjugated
PRESS RELEASE

published on 05/28/2024 at 13:00, 6 months 24 days ago

Secarna Pharmaceuticals and Orbit Discovery enter collaboration to discover and develop peptide-conjugated targeted antisense oligonucleotide therapeutics
Secarna Pharmaceuticals and Orbit Discovery collaborate to develop peptide-conjugated targeted antisense oligonucleotide therapeutics, expanding treatment options for various diseases

Collaboration Secarna Pharmaceuticals Orbit Discovery Peptide-Conjugated Antisense Oligonucleotide Therapeutics

Published on 12/21/2024 at 01:30, 13 hours 15 minutes ago

Quantum Biopharma Announces Closing of Second Tranche
Published on 12/21/2024 at 01:30, 13 hours 15 minutes ago

iMetal Resources Closes First Tranche of Previously Announced Non-Brokered Private Placement
Published on 12/21/2024 at 00:05, 14 hours 40 minutes ago

Chloeta Awarded GSA OASIS+ IDIQ Contract for Intelligence, Federal Civilian and Defense Support Services
Published on 12/21/2024 at 00:00, 14 hours 45 minutes ago

Amarc Announces Loan Extension
Published on 12/20/2024 at 23:30, 15 hours 15 minutes ago

Boron One Announces Extension to Early Warrant Exercise Incentive Program

View all ACCESSWIRE

Published on 12/21/2024 at 00:51, 13 hours 54 minutes ago

Acquisition of PSI Transcom GmbH by CHAPTERS platform Altamount Software GmbH
Published on 12/21/2024 at 00:45, 14 hours ago

EQS-Adhoc: PSI sells the Mobility business unit
Published on 12/20/2024 at 19:10, 19 hours 35 minutes ago

Funding Circle Plc: POS-Transaction in Own Shares
Published on 12/20/2024 at 18:56, 19 hours 49 minutes ago

CPI PROPERTY GROUP – Progress on Key Initiatives
Published on 12/20/2024 at 18:00, 20 hours 45 minutes ago

ARYZTA AG Announces New Board Technology Committee

View all EQS

Published on 12/21/2024 at 12:17, 2 hours 27 minutes ago

AXA announces the signing of a share purchase agreement with BNP Paribas relating to the sale of AXA IM
Published on 12/20/2024 at 18:00, 20 hours 45 minutes ago

Capital increase through exercise of subscription rights
Published on 12/20/2024 at 17:55, 20 hours 50 minutes ago

Disclosure of trading in own shares from 16/12/2024 to 20/12/2024
Published on 12/20/2024 at 14:00, 1 day ago

Safran: Woodward Signs Agreement to Acquire Safran’ s Electromechanical Actuation Business based in North America
Published on 12/19/2024 at 18:30, 1 day 20 hours ago

Share capital decrease by way of treasury shares cancellation

View all LES ECHOS COMFI WIRE

News